Europe Vaccines Market

The Europe vaccines market (excluding COVID-19) is projected to reach USD 13.74 billion by 2030 from USD 9.97 billion in 2025, at a CAGR of 6.6%. The growth of the market is attributed to several key factors, such as high disease surveillance, an aging population, and adult immunization expansion.

Several key players in the Europe vaccines market (excluding COVID-19) with a strong footprint include GSK Plc. (UK), Sanofi (France), Bavarian Nordic (Denmark), AstraZeneca Plc (UK), CSL (Australia), Pfizer (US), Merck & Co., Inc. (US), and Johnson & Johnson Services, Inc. (US). Companies in the European vaccines market are scaling beyond traditional vaccine production through high-throughput, automated platforms covering advanced antigen preparation, viral vector manufacturing, mRNA synthesis, and specialized reagents targeting complex biologics and combination vaccine workflows. By adding new production capacity and launching integrated hardware-software ecosystems, they aim to strengthen European presence, supporting vaccine development programs across discovery, translational research, clinical trials, and public health applications for precision immunization strategies.

To know about the assumptions considered for the study download the pdf brochure

In February 2025, GSK announced the US Food and Drug Administration (FDA) approval for Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which commonly cause invasive meningococcal disease (IMD).

 GSK Plc. (UK)

GSK leads as a significant European vaccines player, combining advanced viral vector platforms like MVA-BN for next-generation vaccines, automated fill-finish lines, and digital manufacturing software for scalable production of complex vaccines such as RSV (Arexvy), shingles (Shingrix), and next-generation pneumococcal formulations. By integrating multi-billion-euro facilities in Belgium and the UK, the company positions itself as a one-stop partner for biopharma and public health organizations needing high-volume, reliable vaccine supply to drive European immunization programs.

Sanofi (France)

Sanofi excels in European vaccine development, integrating cutting-edge mRNA technology, lipid nanoparticle production, and adaptable manufacturing flows with intelligent software for scaling complex vaccines such as influenza, COVID boosters, and RSV-hMPV combinations. Significant investments post-pandemic, including an mRNA center in France, a modulus facility nearby, and expanded lipid capacity in the region, position Sanofi as a full-spectrum provider for pharmaceutical collaborators and public organizations needing consistent, high-volume vaccine delivery.

Bavarian Nordic (Denmark)

Bavarian Nordic thrives as a targeted European vaccines specialist, leveraging its unique MVA-BN vector platform, robotic fill-finish operations, and refined bioprocessing systems to ramp up production of niche vaccines like mpox, Ebola, and therapeutic candidates. Enhancements at its Danish base and a new site in Germany establish the company as an end-to-end ally for industry partners and health authorities pursuing dependable, substantial vaccine supplies for outbreak response and routine programs.

Market Ranking

Many European vaccine companies are advancing beyond conventional manufacturing into high-throughput, automated systems encompassing sophisticated antigen processing, viral vector production, mRNA formulation, and custom reagents for intricate biologics and multi-valent pipelines. GSK harnesses adjuvant technologies and upgraded Belgian/UK sites for shingles and RSV breakthroughs. Sanofi pioneers mRNA ecosystems with French centers excelling in flu and combo RSV-hMPV vaccines. Bavarian Nordic masters MVA-BN vectors via Danish/German expansions for mpox and Ebola readiness. AstraZeneca optimizes viral vector platforms through Swedish and UK facilities, driving next-gen universal flu and oncology candidates. CSL Seqirus integrates egg-free cell-based methods with Austrian/Swiss upgrades for enhanced influenza and pandemic preparedness. These seamless hardware-software frameworks enable end-to-end discovery-to-commercialization, establishing them as comprehensive allies accelerating targeted vaccination strategies for biopharma partners and public health initiatives across Europe.

Related Reports:

Europe Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com